Growth Metrics

Novavax (NVAX) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Novavax (NVAX) over the last 15 years, with Q3 2025 value amounting to $34.2 million.

  • Novavax's Receivables - Net fell 6670.4% to $34.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.2 million, marking a year-over-year decrease of 6670.4%. This contributed to the annual value of $116.0 million for FY2024, which is 6196.99% down from last year.
  • According to the latest figures from Q3 2025, Novavax's Receivables - Net is $34.2 million, which was down 6670.4% from $226.4 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Receivables - Net ranged from a high of $478.2 million in Q1 2022 and a low of $21.4 million during Q1 2024
  • Moreover, its 5-year median value for Receivables - Net was $111.6 million (2022), whereas its average is $161.2 million.
  • Per our database at Business Quant, Novavax's Receivables - Net soared by 74037.4% in 2022 and then crashed by 9011.84% in 2024.
  • Novavax's Receivables - Net (Quarter) stood at $455.0 million in 2021, then plummeted by 78.85% to $96.2 million in 2022, then soared by 216.93% to $304.9 million in 2023, then tumbled by 61.97% to $116.0 million in 2024, then crashed by 70.53% to $34.2 million in 2025.
  • Its last three reported values are $34.2 million in Q3 2025, $226.4 million for Q2 2025, and $52.2 million during Q1 2025.